Montelukast in the treatment of asthma

S. Centanni, P. Santus

Research output: Contribution to journalArticlepeer-review


Asthma is a socially relevant inflammatory disease of the airways. Although symptoms can be discontinuous, airways inflammation needs a continuous care consisting in early correct diagnosis, prevention of asthma attacks, long term therapy, educational programs and constant information to patients. Steps in therapy presently look as the most appropriate strategy in asthma. In the recent years the most convincing advances concern characterization of leukotrienes; these substances are produced by the action of 5-lipoxygenase on arachidonic acid and are key mediators in allergy and inflammation. Cysteinyl-leukotrienes in particular play a fundamental role in pathophysiology of asthma. This is the reason why molecules have been developed which are presently utilized in the therapy of asthma, since they are characterized by a mechanism of antagonization to the receptors for cysteinyl-leukotrienes. Such receptorial antagonists of leukotrienes are clearly active in chronic asthma, exercise-induced bronchoconstriction, aspirin-induced asthma. These drugs are a novel therapeutical approach in asthma and look essential in easing patients' compliance to daily needed therapy.

Original languageEnglish
Pages (from-to)48-53
Number of pages6
JournalGIMT - Giornale Italiano delle Malattie del Torace
Issue number1
Publication statusPublished - 2002


  • Asthma
  • Leukotrienes
  • Montelukast

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine


Dive into the research topics of 'Montelukast in the treatment of asthma'. Together they form a unique fingerprint.

Cite this